Latest news and press releases about Profound Medical Corp. (PROF): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland.
Price
| Price | $5.89 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 4.06 |
| EV / EBITDA | -5.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -62.45% |
| Return on Invested Capital | -60.49% |
| Return on Assets | -52.05% |
| Gross Margin | 71.73% |
| Operating Margin | -184.35% |
| Net Margin | -170.92% |
Related companies: ARMP · AVR · CATX · LNSR · MXCT · NNOX · OWLT
Explore sector: Healthcare · Medical - Devices
More sections of PROF: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks